Similarly, Ghaffari-Nazari et al. (81) observed that presence of PADRE adjuvant in a vaccine formulation comprising multi-epitope protein and CpG-oligodeoxynucleotides (CpG-ODN) promoted an improvement in the anti-tumor (lobular carcinoma) immune response, by inducing expansion of CD4+ and CD8+ IFN-γ producing subpopulations. This evidence concerns the gene CD4 and neoplasm.